RxDoctor Payments Data

Andrew Goldsweig, MD

Interventional Cardiology · Omaha, NENPI 1457594681

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,270 of the $48,794 with a category attached, or 68.2%. 13 manufacturers reported payments, led by Philips North America LLC at 38.6% of the total. 2025 is the largest year on record at $23,549, more than ten times the $1,367 reported in 2019.

$48,794in general payments, 2019–2025

Across 90 payments — averaging $542.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$19K
  • Abbott$18K
  • Boston Scientific$5K
  • Edwards Lifesciences$2K
  • Medtronic$2K
  • Inari Medical, Inc.$1K
  • plus $2K from 7 others
$661,715in research payments, 2019–2025

Across 135 payments — averaging $4901.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • M.a. Med Alliance S.A.$335K
  • Boston Scientific$186K
  • Surmodics, Inc.$64K
  • Medtronic$51K
  • Abbott$27K

What the payments were for

  • Consulting fees$33,27068%
  • Speaking & faculty fees$4,4009%
  • Travel & lodging$8,32617%
  • Food & beverage$2,7986%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Philips North America LLC6$18,811
Abbott32$18,448
Boston Scientific19$4,892
Edwards Lifesciences3$1,859
Medtronic(2 entities)12$1,564
Inari Medical, Inc.3$1,250
Abiomed5$982
Occlutech US LLC1$400
Cordis US CORP.4$306
Chiesi USA, Inc.2$212
Biomarin Pharmaceutical Inc.1$31
Beckman Coulter, Inc.1$23
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,794 in reported general payments places this provider in the 85th percentile of 50 interventional cardiology providers in Nebraska.

See all interventional cardiology providers in Nebraska

Medicare billing

Part B allowed, 2024
$289,516
Medicare patients
6,056
Services billed
10,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan76$116,649
FarxigaDapagliflozin Propanediol54$66,856
XareltoRivaroxaban14$13,276
JardianceEmpagliflozin13$12,363
ClopidogrelClopidogrel Bisulfate159$2,337
Metoprolol Succinate110$1,674
Atorvastatin Calcium40$610
Losartan Potassium55$581
Spironolactone46$325
Carvedilol31$291
Amlodipine Besylate27$257
Rosuvastatin Calcium12$236
Doxazosin Mesylate12$116
Lisinopril14$109
Furosemide25$100

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →